Sol-Gel Technologies (SLGL) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 50.5% versus a loss of 57.0%. Over five years, SLGL leads with a -28.4% price change compared with -85.0% for TRDA. Sol-Gel Technologies is the larger company by market cap ($180.6 million vs $170.3 million), about 1.1 times the size.
Sol-Gel Technologies converts more of its revenue into profit, with a net margin of -31.6% versus -565.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLGL | TRDA |
|---|---|---|
| Share price | $55.17 | $4.35 |
| Market cap | $180.63M | $170.30M |
| 1-day change | +2.02% | -6.25% |
| YTD return | +30.92% | -57.68% |
| 1-year return | +50.53% | -56.97% |
| 5-year return | -28.44% | -84.95% |
| EPS (TTM) | $-5.22 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $19.39M | $25.42M |
| Revenue growth (YoY) | +68.04% | -87.94% |
| Net income (latest FY) | $-6.13M | $-143.75M |
| Operating margin | -38.88% | -621.13% |
| Net margin | -31.60% | -565.48% |
| 52-week high | $97.97 | $16.45 |
| 52-week low | $34.47 | $4.11 |
| Distance from 52-week high | -43.69% | -73.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +181.86% | +308.05% |
| Average volume | 47.38K | 401.15K |
| Shares outstanding | 3.27M | 39.15M |
| Employees | 28 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed TRDA by 107.5 percentage points over the past year.
- Sol-Gel Technologies is more profitable, keeping -31.6 cents of every revenue dollar as net income versus -565.5 cents for Entrada Therapeutics.
- Sol-Gel Technologies grew revenue faster in its latest fiscal year (+68.04% vs -87.94%).
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
SLGL vs TRDA FAQ
Which is bigger, Sol-Gel Technologies or Entrada Therapeutics?
Sol-Gel Technologies (SLGL) is larger, with a market capitalization of $180.63M compared with $170.30M for Entrada Therapeutics (TRDA).
Which stock has performed better over the past year, SLGL or TRDA?
SLGL returned +50.53% over the past 12 months, compared with -56.97% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are Sol-Gel Technologies and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.